These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21383673)

  • 1. Arterial pathology in canine mucopolysaccharidosis-I and response to therapy.
    Lyons JA; Dickson PI; Wall JS; Passage MB; Ellinwood NM; Kakkis ED; McEntee MF
    Lab Invest; 2011 May; 91(5):665-74. PubMed ID: 21383673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
    Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
    Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.
    Di Domenico C; Villani GR; Di Napoli D; Reyero EG; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2005 Jan; 16(1):81-90. PubMed ID: 15703491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I.
    Nenninger A; Ben-Shlomo G; Allbaugh R; Valentine B; Snella E; Jens J; Ellinwood NM; Smith J
    J Inherit Metab Dis; 2023 Mar; 46(2):348-357. PubMed ID: 36601751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
    Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
    Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy.
    Di Domenico C; Di Napoli D; Gonzalez Y Reyero E; Lombardo A; Naldini L; Di Natale P
    Hum Gene Ther; 2006 Nov; 17(11):1112-21. PubMed ID: 17044753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic and biochemical studies of canine mucopolysaccharidosis I.
    Shull RM; Helman RG; Spellacy E; Constantopoulos G; Munger RJ; Neufeld EF
    Am J Pathol; 1984 Mar; 114(3):487-95. PubMed ID: 6320652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
    Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
    Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
    Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
    J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning and characterization of cDNA encoding canine alpha-L-iduronidase. mRNA deficiency in mucopolysaccharidosis I dog.
    Stoltzfus LJ; Sosa-Pineda B; Moskowitz SM; Menon KP; Dlott B; Hooper L; Teplow DB; Shull RM; Neufeld EF
    J Biol Chem; 1992 Apr; 267(10):6570-5. PubMed ID: 1551868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.
    Herati RS; Ma X; Tittiger M; Ohlemiller KK; Kovacs A; Ponder KP
    J Gene Med; 2008 Sep; 10(9):972-82. PubMed ID: 18613275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.